2023-2030 年按产品类型、样品类型、技术、应用、最终用途、细分趋势分列的美国传染病诊断学市场规模、份额和趋势分析报告

美国传染病诊断市场的增长和趋势

根据 Grand View Research, Inc. 的最新报告，美国传染性呼吸道疾病诊断市场预计到 2030 年将达到 92 亿美元，2023 年至 2030 年的复合年增长率为 -10.1%。我来了。

由于 COVID-19 测试的减少，市场预计会下降。然而，美国传染性呼吸道疾病诊断市场仍然是技术进步、传染性呼吸道疾病患病率增加以及开发创新产品以满足不断增长的市场需求的主要驱动力。预计将受到企业高研发投资的推动、政府和非政府组织。

例如，2021 年 1 月，生物医学高级研究与发展局 (BARDA) 分别资助 QIAGEN LLC 和 DiaSorin Molecular LLC 598,000 美元和 679,000 美元，以加强 COVID-19 检测试剂盒和仪器的开发。

用于疾病诊断的创新产品的推出有望推动美国呼吸道感染市场的增长。2020 年 4 月，Bio-Rad Laboratories, Inc. 宣布了一种用于诊断 COVID-19 患者的免疫检测试剂盒。这些是基于血液的免疫测定试剂盒。在最初的初步免疫测定性能中，该检测试剂盒在 >700 名患者中表现出 >99.0% 的特异性。

PerkinElmer 还于 2022 年 9 月获得美国 FDA 的批准，可以使用 T 细胞选择试剂检测试剂盒进行自动结核病检测。该产品使用全球监管的酶联免疫吸附点 (ELISPOT) 干扰素-γ 释放测定来检测潜伏性结核感染。这种 ELISPOT 测试使实验室能够为潜伏性结核病患者提供准确的结果。因此，传染性呼吸道疾病诊断技术的进步正在推动市场发展。

此外，分子诊断学通过提供快速有效的结果在传染病检测中发挥重要作用。根据美国疾病控制和预防中心 (CDC) 的数据，2021 年结核病的估计发病率为每 10 万人 2.4 例。同样，根据美国胸科学会的数据，肺炎每年影响约 100 万人，并有 50,000 人死于该病。因此，预计呼吸道感染髮病率的增加将在研究期间推动美国传染性呼吸道疾病诊断市场。

另一方面，模糊的监管框架和高昂的诊断成本可能会在研究期间阻碍美国传染性呼吸道疾病诊断市场。与分子和免疫检测相关的高成本以及缺乏替代检测产品也是导緻美国传染性呼吸道疾病诊断产品价格上涨的主要原因。

然而，医疗保健当局正在采取措施减轻製造商的高成本负担。从美国 FDA 获得的用于 COVID-19 测试的 EUA 有望最大限度地降低开发成本，并加快将它们提供给更多实验室的过程。因此，降低开发成本有望提高医疗保健专业人员和患者对该测试的负担能力。

美国传染性呼吸系统疾病诊断市场报告要点。

• 2022年传染性呼吸道疾病诊断市场归因于高使用率，耗材板块收入占比约为65.78%。化验和测试套件的研究和开发的增加以及对计数器和自我测试产品以及护理点的需求增加预计将推动该细分市场的增长。
• 按样本类型划分，鼻咽拭子将在2022年占据市场主导地位，预计份额为60.61%，在快速抗原检测、直接萤光抗体、聚合酶链反应等各种检测中应用广泛，需求不断增加。 .
• 2022 年，由于对用于诊断 COVID-19、流感、RSV 等的 RT-PCR 检测的需求增加，分子诊断领域以 63.74% 的收入份额主导了传染性呼吸道疾病诊断市场。
• 由于发病率高、产品批准增加以及创新产品研发增加，COVID-19 细分市场在 2022 年以 91.65% 的份额主导了美国传染性呼吸道疾病诊断市场。然而，随着美国正在实施的大规模疫苗接种活动降低了该病的发病率，这一比例预计到 2030 年将降至 69.97%。

目录

第一章 调查方法和范围

• 市场细分和范围
  • 段范围
• 调查方法
• 信息采购
  • 购买的数据库：
  • GVR内部数据库
  • 次要信息
  • 初步调查
  • 初步调查详情
• 信息或数据分析
  • 数据分析模型
• 市场製定和验证
• 型号详情
  • 商品流向分析
    • 方法：产品流方法
• 调查假设
• 二级信息列表
• 缩略语表
• 目的

第二章执行摘要

• 市场快照
• 片段快照（1/3）
• 片段快照（2/3）
• 细分快照（第 3 个，共 3 个）
• 竞争格局的快照

3. 美国传染性呼吸系统疾病诊断市场变量、趋势和范围

• 母公司市场展望
• 绘製渗透率和增长前景
• 市场驱动力分析
  • 美国传染性呼吸道疾病的高流行率
  • 呼吸系统疾病检测的技术进步
  • 增加对呼吸系统疾病检测的研发投入
• 市场约束因素分析
  • 诊断产品的高价
  • 存在模棱两可的监管框架
• SWOT 分析，按因素（政治和法律、经济、技术）
• 行业分析 - 搬运工
  • 监管框架
  • 赎回场景

4 美国传染性呼吸系统疾病诊断市场：细分分析，按产品类型，2018-2030 年（百万美元）

• 定义和范围
• 美国传染性呼吸系统疾病诊断市场：产品类型变化分析
• 机器
  • 影像学检查
  • 呼吸器
  • 其他乐器
• 消耗品
• 服务

5 美国传染性呼吸系统疾病诊断市场：细分分析，按样本类型，2018-2030 年（百万美元）

• 定义和范围
• 美国传染性呼吸系统疾病诊断市场：样本类型变异分析
• 唾液
• 鼻咽拭子 (Nps)
• 前鼻区
• 血液
• 其他

6 美国传染性呼吸系统疾病诊断市场：细分分析，按技术，2018-2030 年（百万美元）

• 定义和范围
• 美国传染性呼吸系统疾病诊断市场：技术波动分析
• 免疫测定
• 分子诊断
• 微生物学
• 其他技术

7 美国传染性呼吸系统疾病诊断市场：细分分析，按应用，2018-2030（百万美元）（'000s）

• 美国传染性呼吸系统疾病诊断市场：应用差异分析
• COVID-19
  • COVID-19 市场，2018-2030（000 卷）
• 流感
  • 2018-2030 年流感市场（000 年代）
• 呼吸道合胞病毒
  • 呼吸道合胞病毒市场，2018-2030（000 年代）
• 结核
  • 2018-2030 年结核病市场（000 年代）
• 链球菌试验
  • 链球菌检测市场，2018-2030（卷 '000s）
• 其他呼吸道疾病检查
  • 其他呼吸系统疾病检测市场，2018-2030（卷 '000s）

8 美国传染病呼吸系统疾病诊断市场：细分分析，按最终用途，2018-2030 年（百万美元）

• 美国传染性呼吸系统疾病诊断市场：最终用途变化分析
• 医院
• 诊断实验室
• 诊所
• 其他最终用户

9 美国传染性呼吸系统疾病诊断市场：竞争分析

• 参会概况
• 财务绩效
• 进入公司
  • 市场领导者
    • 2022 年美国传染性呼吸系统疾病诊断市场份额分析
  • 战略规划
    • 扩张
    • 获得
    • 合作
    • 产品/服务发布
    • 合伙
    • 其他
  • 供应商情况
    • 经销商和渠道合作伙伴名单
    • 主要客户
• 竞争仪錶盘分析
  • 民营企业
    • 初创公司/技术颠覆者/创新者名单
    • 区域网络图
    • Abbott
    • Koninklijke Philips N.V.
    • Siemens Healthcare GmbH
    • BIOMERIEUX
    • Danaher
    • QIAGEN
    • BD
    • F. Hoffmann-La Roche Ltd
    • Quidel Corporation
    • Thermo Fisher Scientific, Inc.

U.S. Infectious Respiratory Disease Diagnostics Market Growth & Trends:

The U.S. infectious respiratory disease diagnostics market is expected to reach USD 9.20 billion by 2030, registering a CAGR of -10.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to decline due to the decrease in COVID-19 testing. However, the U.S. infectious respiratory disease diagnostics market is expected to be driven by technological advancements, an increase in the prevalence of infectious respiratory diseases, and high R&D investments by the key players, government, & NGOs to develop novel & innovative products to address the increased market demand.

For instance, in January 2021, Biomedical Advanced Research and Development Authority (BARDA) funded USD 598,000 and USD 679,000 to QIAGEN LLC and DiaSorin Molecular LLC, respectively to enhance the development of COVID-19 test kits and instruments.

The introduction of innovative products used for disease diagnosis is anticipated to fuel the U.S. respiratory infectious disease market growth. In April 2020, Bio-Rad Laboratories, Inc. introduced immunoassay test kits for the diagnosis of COVID-19 patients. These were blood-based immunoassay test kits. In the initial preliminary performance of the immunoassay, the test kit demonstrated a specificity of more than 99.0% in more than 700 patients.

In addition, PerkinElmer, Inc. received approval from the U.S. FDA for the use of a T-cell select reagent test kit for the automation of its tuberculosis spot in September 2022. It uses a globally regulated enzyme-linked immunosorbent spot (ELISPOT) interferon-gamma release assay to detect latent tuberculosis infection. This ELISPOT test enables laboratories to offer accurate results to patients with latent tuberculosis. Thus, technological advancements in infectious respiratory disease diagnostics are fueling the market.

Moreover, molecular diagnostics play an important role in infectious disease testing by offering quick & effective results. According to the Centers for Disease Prevalence and Prevention (CDC), the estimated incidence rate of tuberculosis was 2.4 cases per 100,000 populations as of 2021. Similarly, according to the American Thoracic Society, pneumonia affects around 1.0 million people annually, and 50,000 die from this disease. Thus, the increasing incidence of respiratory infections is expected to drive the U.S. infectious respiratory disease diagnostics market during the study period.

On the other hand, the presence of ambiguous regulatory frameworks and high prices of diagnostics products may hamper the U.S. infectious respiratory disease diagnostics market during the study period. High costs related to molecular & immunoassay tests and lack of alternative testing products are the other major reasons for increased prices of infectious respiratory disease diagnostic products in the U.S.

However, healthcare authorities have taken steps to reduce the burden of high costs on manufacturers. EUA received from the U.S. FDA for COVID-19 tests is expected to minimize development costs and accelerate the process to increase the availability at more testing sites. Hence, a decrease in development costs is anticipated to increase the affordability of tests for healthcare providers and patients.

U.S. Infectious Respiratory Disease Diagnostics Market Report Highlights:

• The consumables segment dominated the infectious respiratory illness diagnostics market in 2022 with a revenue share of around 65.78%, which can be attributed to high usage rates. An increase in R&D for assays and testing kits, coupled with a rise in demand for the point-of-care in addition to the counter & self-test products is expected to drive the segment growth

• Based on the sample type, the market was dominated by nasopharyngeal swabs with an estimated share of 60.61% in 2022, due to wide applications in conducting various tests such as rapid antigen detection tests, direct fluorescent antibody, and polymerase chain reaction coupled with increased demand

• In 2022, the molecular diagnostics segment dominated the infectious respiratory disease diagnostics market with a revenue share of 63.74%, due to the increased demand for RT-PCR tests used for the diagnosis of COVID-19, influenza, RSV, and others

• The COVID-19 segment dominated the U.S. infectious respiratory disease diagnostics market with a share of 91.65% in 2022, due to the high incidence, increased product approvals, and rise in R&D pertaining to innovative products. However, its share is expected to decline to 69.97% by 2030 due to the mass vaccination drives being conducted in the U.S., which, in turn, will reduce the rate of diseases

Table of Contents

Chapter 1 Research Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Scope
  • 1.1.2 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database:
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach: Commodity Flow Approach
• 1.7 Research Assumptions
• 1.8 List Of Secondary Sources
• 1.9 List Of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3
  • 1.10.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot (1/3)
• 2.3 Segment Snapshot (2/3)
• 2.4 Segment Snapshot (3/3)
• 2.5 Competitive Landscape Snapshot

Chapter 3 U.S. Infectious Respiratory Disease Diagnostics Market Variables, Trends, And Scope

• 3.1 Parent Market Outlook
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Market Driver Analysis
  • 3.3.1 High Prevalence Of Infectious Respiratory Diseases In U.S.
  • 3.3.2 Technological Advancement In Respiratory Disease Testing
  • 3.3.3 Rising R&D Investments In Respiratory Disease Testing
• 3.4 Market Restraint Analysis
  • 3.4.1 High Prices Of Diagnostic Products
  • 3.4.2 Presence Of Ambiguous Regulatory Framework
• 3.5 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
• 3.6 Industry Analysis - Porter's
  • 3.6.1 Regulatory Framework
  • 3.6.2 Reimbursement Scenario

Chapter 4 U.S. Infectious Respiratory Disease Diagnostics Market: Segment Analysis, By Product Type, 2018 - 2030 (USD Million)

• 4.1 Definitions And Scope
• 4.2 U.S. Infectious Respiratory Disease Diagnostics Market: Product Type Movement Analysis
• 4.3 Instruments
  • 4.3.1 Instruments Market, 2018 - 2030 (USD Million)
  • 4.3.2 Imaging Tests
    • 4.3.2.1 Imaging Tests Market, 2018 - 2030 (USD Million)
  • 4.3.3 Respiratory Measurement Devices
    • 4.3.3.1 Respiratory Measurement Devices Market, 2018 - 2030 (USD Million)
  • 4.3.4 Other Instruments
    • 4.3.4.1 Other Instruments Market, 2018 - 2030 (USD Million)
• 4.4 Consumables
  • 4.4.1 Consumables Market, 2018 - 2030 (USD Million)
• 4.5 Services
  • 4.5.1 Services Market, 2018 - 2030 (USD Million)

Chapter 5 U.S. Infectious Respiratory Disease Diagnostics Market: Segment Analysis, By Sample Type, 2018 - 2030 (USD Million)

• 5.1 Definitions & Scope
• 5.2 U.S. Infectious Respiratory Disease Diagnostics Market: Sample Type Movement Analysis
• 5.3 Saliva
  • 5.3.1 Saliva Market, 2018 - 2030 (USD Million)
• 5.4 Nasopharyngeal Swabs (Nps)
  • 5.4.1 Nasopharyngeal Swabs (Nps) Market, 2018 - 2030 (USD Million)
• 5.5 Anterior Nasal Region
  • 5.5.1 Anterior Nasal Region Market, 2018 - 2030 (USD Million)
• 5.6 Blood
  • 5.6.1 Blood Market, 2018 - 2030 (USD Million)
• 5.7 Others
  • 5.7.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 U.S. Infectious Respiratory Disease Diagnostics Market: Segment Analysis, By Technology, 2018 - 2030 (USD Million)

• 6.1 Definitions And Scope
• 6.2 U.S. Infectious Respiratory Disease Diagnostics Market: Technology Movement Analysis
• 6.3 Immunoassay
  • 6.3.1 Immunoassay Market, 2018 - 2030 (USD Million)
• 6.4 Molecular Diagnostics
  • 6.4.1 Molecular Diagnostics Market, 2018 - 2030 (USD Million)
• 6.5 Microbiology
  • 6.5.1 Microbiology Market, 2018 - 2030 (USD Million)
• 6.6 Other Technologies
  • 6.6.1 Other Technologies Market, 2018 - 2030 (USD Million)

Chapter 7 U.S. Infectious Respiratory Disease Diagnostics Market: Segment Analysis, By Application, 2018 - 2030 (USD Million) ('000s)

• 7.1 U.S. Infectious Respiratory Disease Diagnostics Market: Application Movement Analysis
• 7.2 Covid-19
  • 7.2.1 Covid-19 Market, 2018 - 2030 (USD Million)
  • 7.2.2 Covid-19 Market, 2018 - 2030 (Volume '000s)
• 7.3 Influenza
  • 7.3.1 Influenza Market, 2018 - 2030 (USD Million)
  • 7.3.2 Influenza Market, 2018 - 2030 (Volume '000s)
• 7.4 Respiratory Syncytial Virus
  • 7.4.1 Respiratory Syncytial Virus Market, 2018 - 2030 (USD Million)
  • 7.4.2 Respiratory Syncytial Virus Market, 2018 - 2030 (Volume '000s)
• 7.5 Tuberculosis
  • 7.5.1 Tuberculosis Market, 2018 - 2030 (USD Million)
  • 7.5.2 Tuberculosis Market, 2018 - 2030 (Volume '000s)
• 7.6 Streptococcus Testing
  • 7.6.1 Streptococcus Testing Market, 2018 - 2030 (USD Million)
  • 7.6.2 Streptococcus Testing Market, 2018 - 2030 (Volume '000s)
• 7.7 Other Respiratory Disease Testing
  • 7.7.1 Other Respiratory Disease Testing Market, 2018 - 2030 (USD Million)
  • 7.7.2 Other Respiratory Disease Testing Market, 2018 - 2030 (Volume '000s)

Chapter 8 U.S. Infectious Respiratory Disease Diagnostics Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)

• 8.1 U.S. Infectious Respiratory Disease Diagnostics Market: End-Use Movement Analysis
• 8.2 Hospitals
  • 8.2.1 Hospitals Market, 2018 - 2030 (USD Million)
• 8.3 Diagnostic Laboratories
  • 8.3.1 Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
• 8.4 Physician Offices
  • 8.4.1 Physician Offices Market, 2018 - 2030 (USD Million)
• 8.5 Other End Users
  • 8.5.1 Other End-Users Market, 2018 - 2030 (USD Million)

Chapter 9 U.S. Infectious Respiratory Disease Diagnostics Market: Competitive Analysis

• 9.1 Participants' Overview
• 9.2 Financial Performance
• 9.3 Participant Categorization
  • 9.3.1 Market Leaders
    • 9.3.1.1 U.S. Infectious Respiratory Disease Diagnostics Market Share Analysis, 2022
  • 9.3.2 Strategy Mapping
    • 9.3.2.1 Expansion
    • 9.3.2.2 Acquisition
    • 9.3.2.3 Collaborations
    • 9.3.2.4 Product/Service Launch
    • 9.3.2.5 Partnerships
    • 9.3.2.6 Others
  • 9.3.3 Vendor Landscape
    • 9.3.3.1 List Of Distributors And Channel Partners
    • 9.3.3.2 Key Customers
• 9.4 Competitive Dashboard Analysis
  • 9.4.1 Private Companies
    • 9.4.1.1 List of Emerging Companies/Technology Disruptors/ Innovators
    • 9.4.1.2 Regional Network Map include:
    • 9.4.1.2.1 Abbott
    • 9.4.1.2.2 Koninklijke Philips N.V.
    • 9.4.1.2.3 Siemens Healthcare GmbH
    • 9.4.1.2.4 BIOMERIEUX
    • 9.4.1.2.5 Danaher
    • 9.4.1.2.6 QIAGEN
    • 9.4.1.2.7 BD
    • 9.4.1.2.8 F. Hoffmann-La Roche Ltd
    • 9.4.1.2.9 Quidel Corporation
    • 9.4.1.2.10 Thermo Fisher Scientific, Inc.

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 CPT codes reimbursement of diagnostic tests
• Table 4 U.S. infectious respiratory disease diagnostics market by, product type, 2018 - 2030 (USD Million)
• Table 5 U.S. infectious respiratory disease diagnostics market by, sample type, 2018 - 2030 (USD Million)
• Table 6 U.S. infectious respiratory disease diagnostics market by, technology, 2018 - 2030 (USD Million)
• Table 7 U.S. infectious respiratory disease diagnostics market by, application, 2018 - 2030 (USD Million)
• Table 8 U.S. infectious respiratory disease diagnostics market by, end-use, 2018 - 2030 (USD Million)
• Table 9 Participant's overview
• Table 10 Financial performance
• Table 11 Key companies undergoing expansions
• Table 12 Key companies undergoing acquisitions
• Table 13 Key companies undergoing collaborations
• Table 14 Key companies launching new products/services
• Table 15 Key companies undergoing partnerships
• Table 16 Key companies undertaking other strategies

List of Figures

• Fig. 1 U.S. Infectious Respiratory Disease Diagnostics market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot (By product & sample type)
• Fig. 11 Segment snapshot (By technology type & end-use type)
• Fig. 12 Segment snapshot (By application)
• Fig. 13 Competitive landscape snapshot
• Fig. 14 Penetration and growth prospect mapping
• Fig. 15 U.S. infectious respiratory disease diagnostics market driver impact
• Fig. 16 Number of new tuberculosis cases from 2018-2021, in the U. S.
• Fig. 17 Incidence rate trend of tuberculosis from 2018-2021
• Fig. 18 U.S. infectious respiratory disease diagnostics market restraint impact
• Fig. 19 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
• Fig. 20 Porter's Five Forces Analysis
• Fig. 21 U.S. healthcare reimbursement and financing structure
• Fig. 22 U.S. infectious respiratory disease diagnostics product type outlook: Key takeaways
• Fig. 23 Infectious respiratory disease diagnostics market: Product type movement analysis (USD Million)
• Fig. 24 Instruments market, 2018 - 2030 (USD Million)
• Fig. 25 Imaging tests market, 2018 - 2030 (USD Million)
• Fig. 26 Respiratory measurement devices market, 2018 - 2030 (USD Million)
• Fig. 27 Other instruments market, 2018 - 2030 (USD Million)
• Fig. 28 Consumables market, 2018 - 2030 (USD Million)
• Fig. 29 Services market, 2018 - 2030 (USD Million)
• Fig. 30 U.S. Infectious respiratory disease diagnostics Sample type outlook: Key takeaways
• Fig. 31 U.S. infectious respiratory disease diagnostics market: Sample type movement analysis (USD Million)
• Fig. 32 Saliva market, 2018 - 2030 (USD Million)
• Fig. 33 Nasopharyngeal swabs (NPS) market, 2018 - 2030 (USD Million)
• Fig. 34 Anterior Nasal Region market, 2018 - 2030 (USD Million)
• Fig. 35 Blood market, 2018 - 2030 (USD Million)
• Fig. 36 Others market, 2018 - 2030 (USD Million)
• Fig. 37 U.S. infectious respiratory disease diagnostics technology outlook: Key takeaways
• Fig. 38 U.S. infectious respiratory disease diagnostics market: Technology movement analysis (USD Million)
• Fig. 39 Immunoassay market, 2018 - 2030 (USD Million)
• Fig. 40 Molecular diagnostics market, 2018 - 2030 (USD Million)
• Fig. 41 Microbiology market, 2018 - 2030 (USD Million)
• Fig. 42 Other technologies market, 2018 - 2030 (USD Million)
• Fig. 43 U.S. infectious respiratory disease diagnostics application outlook: Key takeaways
• Fig. 44 U.S. infectious respiratory disease diagnostics application outlook: Key takeaways (Volume 000)
• Fig. 45 U.S. infectious respiratory disease diagnostics market: Application movement analysis (USD Million)
• Fig. 46 U.S. infectious respiratory disease diagnostics market: Application movement analysis (Volume, '000s)
• Fig. 47 COVID-19 market, 2018 - 2030 (USD Million)
• Fig. 48 COVID-19 market, 2018 - 2030 (Volume '000s)
• Fig. 49 Influenza market, 2018 - 2030 (USD Million)
• Fig. 50 Influenza market, 2018 - 2030 (Volume '000s)
• Fig. 51 Respiratory syncytial virus market, 2018 - 2030 (USD Million)
• Fig. 52 Respiratory syncytial virus market, 2018 - 2030 (Volume '000s)
• Fig. 53 Tuberculosis market, 2018 - 2030 (USD Million)
• Fig. 54 Tuberculosis market, 2018 - 2030 (Volume '000s)
• Fig. 55 Streptococcus testing market, 2018 - 2030 (USD Million)
• Fig. 56 Streptococcus testing market, 2018 - 2030 (Volume '000s)
• Fig. 57 Other respiratory disease testing market, 2018 - 2030 (USD Million)
• Fig. 58 Other respiratory disease testing market, 2018 - 2030 (Volume '000s)
• Fig. 59 U.S. Infectious respiratory disease diagnostics end-use outlook: Key takeaways
• Fig. 60 U.S. infectious respiratory disease diagnostics market: End-use movement analysis (USD Million)
• Fig. 61 Hospitals market, 2018 - 2030 (USD Million)
• Fig. 62 Diagnostic laboratories market, 2018 - 2030 (USD Million)
• Fig. 63 Physician offices market, 2018 - 2030 (USD Million)
• Fig. 64 Other end-users' market, 2018 - 2030 (USD Million)
• Fig. 65 Market participant categorization
• Fig. 66 U.S. infectious respiratory disease diagnostics market share analysis, 2022
• Fig. 67 Strategic framework
• Fig. 68 Company market position analysis
• Fig. 69 Regional network map